SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DewDiligence_on_SI who wrote (405)9/15/2006 1:28:22 PM
From: tuck   of 447
 
Interesting assay developed by Acadia(!) suggests that Tarceva might get a little farther into the primary tumor than Iressa. It also expands on the relationship between mutated EGFRs and clinical response, getting a bit farther than previous studies:

Message 22815426

I have no idea why Acadia has developed such an assay, as it does not relate to their neurological focus, but ImClone, Genentech, and OSI might all want to take a close look at this. And some diagnostics company should be able to get it for a decent price if they like it, again because this has little to do with ACAD's development focus.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News